Aims During the post‐discharge phase following a heart failure hospitalization (HFH),
patients are at high risk of early readmission despite standard of care therapy. We examined …

Aims We explored the effect of treatment with ivabradine, a pure heart rate-slowing agent, on
recurrent hospitalizations for worsening heart failure (HF) in the SHIFT trial. Methods and …

Background: Ivabradine, a specific heart rate lowering agent, was shown in the SHIFT study
to reduce time to first hospitalization for worsening heart failure (HF) in chronic systolic HF …

Background Ivabradine is guideline-recommended to reduce heart failure (HF)
hospitalization in patients with stable chronic HF with reduced ejection fraction (EF) …

Aims To test whether the efficacy and safety of the selective heart rate‐reducing agent
ivabradine changes according to age in chronic heart failure (HF) patients. Methods and …

Objective: Ivabradine has been shown to improve symptoms and to reduce rehospitalization
and mortality in patients with severe chronic heart failure (HF). Its indication in acute HF is …

Aims Low systolic blood pressure (SBP) is associated with poor outcomes in heart failure
and complicates management. In a post hoc analysis, we investigated the efficacy and …

A post hoc analysis of Systolic Heart failure treatment with the I f inhibitor ivabradine Trial
(SHIFT) explored the efficacy and safety of ivabradine in severe heart failure (HF) as …

Background We analysed the effect of ivabradine on outcomes in heart failure (HF) patients
on recommended background therapies with heart rates≥ 75 bpm and< 75 bpm in the …

Aims Early start and patient profile‐oriented heart failure (HF) management has been
recommended. In this post hoc analysis from the SHIFT trial, we analysed the treatment …